Conditions: Philadelphia Chromosome Positive CML
Keywords: Chronic Myelogenous Leukemia CML Philadelphia Chromosome Blast crisis Imatinib mesylate
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 260
Healthy volunteers: no

Brief summary:
This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.

Detailed description:

Arms:
arm 1: Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.

Interventions: intervention 1: imatinib mesylate
Intervention descriptions: intervention 1: None

Protocol document: